What is the management of bradycardia (abnormally slow heart rate) in a moribund (dying) patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 4, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Bradycardia in a Moribund Patient

In a moribund (dying) patient with bradycardia, focus on comfort measures and avoid aggressive interventions unless there is a reversible cause and the patient has expressed wishes for full resuscitation. 1

Initial Assessment

Determine goals of care immediately before initiating any treatment, as this fundamentally changes management in moribund patients. 1

  • Assess whether the patient has advance directives or documented wishes regarding resuscitation 1
  • Evaluate if bradycardia represents the terminal phase of underlying disease versus a potentially reversible acute process 1
  • Consider functional status, life expectancy, and quality of life priorities in decision-making 1, 2

If Full Resuscitation is Desired

Immediate Pharmacologic Management

Administer atropine 0.5-1 mg IV as first-line therapy, repeating every 3-5 minutes to a maximum total dose of 3 mg. 1, 3 However, recognize that atropine has significant limitations:

  • Doses less than 0.5 mg may paradoxically worsen bradycardia and should be avoided 1, 3, 4
  • Atropine is likely ineffective in type II second-degree or third-degree AV block with wide QRS complexes, where the block is infranodal 1, 3
  • In moribund patients with severe underlying cardiac disease, atropine may cause paradoxical high-grade AV block 1, 5

Second-Line Interventions

If atropine fails, initiate IV epinephrine infusion at 2-10 mcg/min, titrated to hemodynamic response. 1, 3 This is preferred over dopamine in moribund patients because:

  • Epinephrine provides more potent chronotropic and inotropic effects when urgent support is needed 3
  • Dopamine at 5-10 mcg/kg/min is an alternative but requires more careful titration 1, 3
  • Both agents increase myocardial oxygen demand and may worsen ischemia if present 1, 3

Transcutaneous Pacing

Consider transcutaneous pacing only if the patient remains unstable despite medications and has a potentially reversible cause. 1, 3 Important caveats:

  • Transcutaneous pacing is extremely painful in conscious patients and requires sedation/analgesia 3
  • It serves only as a temporizing measure, not definitive therapy 3
  • In truly moribund patients, pacing may prolong suffering without improving meaningful outcomes 1

If Comfort-Focused Care is Appropriate

Provide symptomatic relief without attempting to correct the bradycardia itself. 1

  • Ensure adequate oxygenation and positioning for comfort 6
  • Treat associated symptoms (dyspnea, anxiety, pain) with appropriate palliative medications 1
  • Avoid atropine, vasopressors, and pacing, as these interventions may prolong the dying process without improving quality of life 1

Critical Pitfalls to Avoid

Do not reflexively treat bradycardia in moribund patients without first establishing goals of care. 1 Common errors include:

  • Administering atropine in patients with infranodal blocks, which can precipitate complete heart block and ventricular standstill 1, 5
  • Using chronotropic agents in acute myocardial infarction, which increases infarct size and worsens outcomes 1, 3
  • Pursuing aggressive interventions (pacing, vasopressors) in patients with terminal illness where bradycardia represents the natural dying process 1
  • Delaying comfort measures while attempting futile resuscitation 1

Special Considerations

In the approximately 20% of patients requiring temporary pacing for stabilization, recognize this is only appropriate if there is a reversible cause and the patient desires aggressive intervention. 7 The 30-day mortality for compromising bradycardia is approximately 5%, but this rises substantially in moribund patients with multiple comorbidities. 7

Aminophylline 6 mg/kg IV over 20-30 minutes may be considered in atropine-resistant bradycardia if the patient is not actively dying and has a reversible cause (such as spinal cord injury or post-cardiac transplant), but this is rarely appropriate in truly moribund patients. 1, 8

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Bradycardia Symptoms and Intervention Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Symptomatic Bradycardia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Immediate Management of Angioedema with Bradycardia

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.